Quick Answer
Climb Bio, Inc. reported Stockholders Equity of $160.47 million for fiscal year 2025.
Climb Bio, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $160.47M | -24.3% |
| 2024 | $211.88M | +96.9% |
| 2023 | $107.60M | -16.4% |
| 2022 | $128.72M | -23.0% |
| 2021 | $167.20M | +769.3% |
| 2020 | -$24.98M | -349.2% |
| 2019 | -$5.56M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $177.00M | -19.1% | -4.7% |
| June 30, 2025 | $185.76M | -16.4% | -3.9% |
| March 31, 2025 | $193.38M | +81.8% | -8.7% |
| December 31, 2024 | $211.88M | +96.9% | -3.2% |
| September 30, 2024 | $218.78M | +99.4% | -1.6% |
| June 30, 2024 | $222.28M | +97.6% | +108.9% |
| March 31, 2024 | $106.38M | -9.0% | -1.1% |
| December 31, 2023 | $107.60M | -16.4% | -2.0% |
- Climb Bio, Inc. showed a decrease of -24.3% in Stockholders Equity compared to the prior fiscal year.
- Over the 2019–2025 period, Climb Bio, Inc.’s stockholders equity has grown by 2985.2% (from -$5.56 million to $160.47 million).
- The most recent figure is from Climb Bio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: